HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mucinex Line Extensions Underscore Adams’ Commitment To Building OTCs

This article was originally published in The Tan Sheet

Executive Summary

A major task facing Adams Respiratory Therapeutics' new VP-OTC Marketing & Business Development Robert Casale will be to plan a Fall 2004 launch of extensions to the firm's Mucinex expectorant brand

You may also be interested in...



Adams Pulls Off Trade For Mucinex Complement

Adams Respiratory Therapeutics is expanding its guaifenesin cough/cold portfolio with the addition of Cornerstone BioPharma's Humibid line

Adams execs

Helmut Albrecht, MD, joins Adams Respiratory Therapeutics to serve as senior VP-R&D, the firm announces Oct. 29. Albrecht will oversee all R&D activities, including clinical development, regulatory issues and new product development; the new exec said Adams "is ready to expand its presence in the respiratory category." Most recently, Albrecht was Novartis Consumer Health/OTC business unit's VP-global preclinical & clinical development. New VP-Regulatory Affairs Susan Witham will report to Albrecht. Witham previously held senior positions at J&J Consumer and Novartis. The appointments follow Adams' recently announced strategic decision to focus on OTCs and expand the Mucinex line (1"The Tan Sheet" May 31, 2004, p. 9)...

Adams Labs Taps Former Novartis Exec, CHPA Chair Valentino For CEO Post

Newly appointed Adams Labs CEO Michael Valentino's primary task will be to decide whether to model the firm as an OTC player or maintain its focus on Rx specialty pharmaceuticals

Related Content

Topics

UsernamePublicRestriction

Register

RS127551

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel